The D299G/T399I Toll-Like Receptor 4 Variant Associates with Body and Liver Fat: Results from the TULIP and METSIM Studies

Peter Weyrich1, Harald Staiger1*, Alena Stančáková2, Fausto Machicao1, Jürgen Machann3, Fritz Schick3, Norbert Stefan1, Johanna Kuusisto2, Markku Laakso2, Silke Schäfer1, Andreas Fritsche1, Hans-Ulrich Häring1

1 Division of Endocrinology, Diabetology, Vascular Disease, Nephrology, Clinical Chemistry, Department of Internal Medicine, Paul-Langerhans-Institute Tübingen, University of Tübingen, Tübingen, Germany, 2 Department of Medicine, Kuopio University Hospital, Kuopio, Finland, 3 Section on Experimental Radiology, University of Tübingen, Germany

Abstract

**Background:** Toll-like-receptor 4 (TLR) is discussed to provide a molecular link between obesity, inflammation and insulin resistance. Genetic studies with replications in non-diabetic individuals in regard to their fat distribution or insulin resistance according to their carrier status of a common toll-like receptor 4 (TLR4) variant (TLR41D299G/G1399I) are still lacking.

**Methodology/Principal Findings:** We performed a cross-sectional analysis in individuals phenotyped for prediabetic traits as body fat composition (including magnetic resonance imaging), blood glucose levels and insulin resistance (oral glucose tolerance testing, euglycemic hyperinsulineemic clamp), according to TLR4 genotype determined by candidate SNP analyses (rs4986790). We analyzed N = 1482 non-diabetic individuals from the TUF/TULIP cohort (South Germany, aged 39 ± 13 y, BMI 28.5 ± 7.9, mean ± SD) and N = 5327 non-diabetic participants of the METSIM study (Finland, males aged 58 ± 6 y, BMI 26.8 ± 3.8) for replication purposes. German TLR41D299GG1/T399I carriers had a significantly increased body fat (XG in rs4986790: +6.98%, p = 0.03, dominant model, adjusted for age, gender) and decreased insulin sensitivity (XG: −15.3%, Matsuda model, p = 0.04; XG: −20.6%, p = 0.016, clamp; both dominant models adjusted for age, gender, body fat). In addition, both liver fat (AG: +49.7%; p = 0.002) and visceral adipose tissue (AG: +8.2%; p = 0.047, both adjusted for age, gender, body fat) were significantly increased in rs4986790 minor allele carriers, and the effect on liver fat remained significant also after additional adjustment for visceral fat (p = 0.014). The analysis in METSIM confirmed increased body fat content in association with the rare G allele in rs4986790 (AG: +1.26%, GG: +11.0%; p = 0.010, additive model, adjusted for age) and showed a non-significant trend towards decreased insulin sensitivity (AG: −0.99%, GG: −10.62%).

**Conclusions/Significance:** TLR41D299GG1/T399I associates with increased total body fat, visceral fat, liver fat and decreased insulin sensitivity in non-diabetic Caucasians and may contribute to diabetes risk. This finding supports the role of TLR4 as a molecular link between obesity and insulin resistance.

Citation: Weyrich P, Staiger H, Stančáková A, Machicao F, Machann J, et al. (2010) The D299G/T399I Toll-Like Receptor 4 Variant Associates with Body and Liver Fat: Results from the TULIP and METSIM Studies. PLoS ONE 5(11): e13980. doi:10.1371/journal.pone.0013980

Editor: Kathrin Maedler, University of Bremen, Germany

Received July 26, 2010; Accepted October 16, 2010; Published November 15, 2010

Copyright: © 2010 Weyrich et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This study was in part supported by a grant from the European Community's FP6 EUGENE2 (LSHM-CT-2004-512013, see also: http://www.eugene2.com) and by a grant from the German Federal Ministry of Education and Research (BMBF) to the German Center for Diabetes Research (DZD e.V.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: harald.staiger@med.uni-tuebingen.de

Introduction

Obesity and excess of saturated free fatty acids (SFFAs) cause low-grade inflammatory processes with subsequent development of insulin resistance, which is a major risk factor for later onset of type 2 diabetes mellitus [1]. As the prevalence of obesity and type 2 diabetes mellitus (T2DM) increases throughout the world with remarkable socio-economic impact [2], it is important to understand the molecular mechanisms that link dietary SFFA intake and endogenous SFFAs derived from adipose tissue lipolysis, respectively, to inflammation.

In this context, toll-like receptor (TLR) signaling moved into the center of current scientific debate [3]. TLRs are transmembrane receptors which play a crucial role in the innate, non-adaptive immune system. The human TLR family comprises at least 13 distinctive proteins (TLR1–TLR13) that are able to recognize typical microbial agents and subsequently facilitate an early immune response via downstream signaling to different signaling pathways (see [4,5,6] for review). The human TLR member characterized best to date is toll-like receptor 4 (TLR4; NM_138554; OMIM 603030), as this signaling molecule is essential for the recognition of bacterial lipopolysaccharides.
(LPS) beyond other microbial agents [7]. LPS represent a key element of gram-negative bacteria and contain fatty acids in their lipid-A domain anchoring LPS into the bacterial cell wall [8]. First evidence that TLR4 not only acts for LPS as a signaling receptor but also for other lipids as e.g. SFFAs came up from studies in macrophages expressing TLR4 mutants [9]. Subsequent studies revealed that TLR4 signaling actually is essential for the development of SFA-induced insulin resistance in different cellular models, e.g. in 3T3L1-adipocytes [10,11] and L6 myotubes [12]. It was also shown that TLR4 mediates the crosstalk between macrophage-induced adipose tissue lipolysis and increased inflammatory activity in both adipocytes and macrophages [13]. In addition, TLR4<sup>−/−</sup> mice are protected against down-regulation of insulin signaling in skeletal muscle upon systemic lipid infusion [11,12], and C3H/Hc mice bearing a loss-of-function mutation in TLR4 do not develop diet-induced obesity or insulin-resistance in skeletal muscle [14], nor do they develop dietary hepatic steatosis [15]. A very recent molecular study provides further insights into the molecular events occurring after SFA-induced TLR4 receptor stimulation, as both TLR4 dimerization and its recruitment to lipid-rafts seem to be influenced by SFFAs [16]. In humans, obese and type 2 diabetic subjects show both an increased TLR4 gene expression and TLR4-dependent activation of the inflammatory signaling molecules IkB/NFkB [17], and dietary restriction results in down-regulation of TLR4 expression [18].

In summary, there is evidence that TLR4 may provide the molecular mechanism that links increased SFFAs in obese subjects to the observed chronic low-grade inflammatory state and subsequent manifestation of insulin resistance. Further evidence for the potential in-vivo relevance of this mechanism would result from genetic studies in populations with common TLR4 mutants. In this regard, two SNPs (rs4986790, rs4986791) in exon 3 of the TLR4 gene (TLR4) causing single amino acid replacements (rs4986790: D299G; rs4986791: T399I) in the extracellular TLR4 domain were shown to be present at allele frequencies between 0.03 and 0.05 in different Caucasian populations [19]. In Europeans, co-segregation (D<sup>2</sup> = 1.0, r<sup>2</sup> = 1.0) of both SNPs occurs [20], probably owing to genetic drift after selection of the TLR4<sup>D299G</sup> mutant in Africa which confers resistance to malaria [21]. As the two non-synonymous SNPs rs4986790/91 in the extracellular domain of TLR4 may bear functional consequences on ligand-binding, many studies focused on the relevance of rs4986790/91 on both the cellular level and in genetic association studies, revealing conflicting results [22].

Most geneticists focused on immunologic and inflammatory phenotypes associating with the TLR4<sup>D299G/T399I</sup> variant [23,24,25,26,27,28], and only a limited number of studies addressing the role of TLR4<sup>D299G/T399I</sup> for diabetic traits are available. While an early study was not able to verify the association of TLR4<sup>D299G/T399I</sup> with changes in diabetes prevalence [29], a recent work supports that male Caucasian TLR4<sup>D299G/T399I</sup> individuals are at higher T2DM risk, dependent on the ratio between (total):(high-density-lipoprotein) cholesterol levels [30]. In addition, increased risk of early onset of diabetic retinopathy was reported for TLR4<sup>D299G/T399I</sup> carriers in Brazil [31]. On the other hand, the prevalence of diabetic neuropathy seemed to be lower in TLR4<sup>D299G/T399I</sup> Caucasian individuals [32], and protection from both T2DM [33] and the metabolic syndrome [34] by TLR4<sup>D299G/T399I</sup> carriers also has been described.

To our knowledge, there are no investigations that have addressed potential prediabetic phenotypes in carriers of the TLR4<sup>D299G/T399I</sup> variant. We, therefore, conducted this genetic association study on TLR4<sup>D299G/T399I</sup> in non-diabetic subgroups of two independent Caucasian populations, namely the TUF/TULIP cohort (South Germany) and the METSIM cohort (Finland). We focused on both body composition parameters as well as insulin resistance in light of above listed TLR4 signaling functions.

**Materials and Methods**

**Study Participants**

TUF/TULIP cohort – 1635 participants of the Tübinger Family Study (TUF) and the Tübingen Lifestyle Intervention Program (TULIP) in South West Germany were analyzed for this study. All volunteers signed informed written consent to the study protocol which was approved by the local medical ethics committee. 153 subjects had to be excluded owing to manifest diabetes or missing data resulting in a total cohort of n = 1482 non-diabetic individuals. The participants (see Table 1 for additional characteristics) did not take any medication known to affect glucose tolerance, and strict abstention from smoking was demanded 24 h before and during the test period including an oral glucose tolerance test (OGTT; all participants, see below) and a hyperinsulinaemic-euglycaemic clamp (N = 502 participants). As described elsewhere [35], the aim of the TULIP study is to provide a broad range of metabolic data of non-diabetic individuals with increased diabetes risk, as e.g. a positive family history of diabetes, a BMI of >27 kg/m<sup>2</sup>, the presence of impaired fasting glucose (IFG) or former gestational diabetes.

METSIM cohort – The METabolic Syndrome In Men (METSIM) Study is a population-based random sample of 6229 Finnish men aged from 45 to 73 years in Eastern Finland (Kuopio, see Table 1) who were phenotyped during a one-day visit to the Clinical Research Unit of the University of Kuopio for diabetes risk and cardiovascular disease variables. All study participants underwent an OGTT, and the study protocol was approved by the local ethics committee. For this study, only non-diabetic METSIM participants were analyzed (N = 5327). However, additional inclusion of METSIM participants with diagnosed diabetes (N = 898) according to the WHO criteria [36] allowed estimation for diabetes risk using logistic regression analysis in a separate analysis.

### Table 1. Clinical characteristics of the TUF-TULIP and METSIM study population.

|                     | TUF-TULIP | METSIM |
|---------------------|-----------|--------|
| **Gender (female/male)** | 978/504  | 0/5327 |
| **IFG/IGT (IFG+IGT)**   | 48/193/59 | 884/503/346 |
| **Age (y)**             | 39±13    | 58±6   |
| **BMI (kg/m<sup>2</sup>)** | 28.5±7.9  | 26.8±3.8 |
| **Body Fat (%)**         | 30.4±10.4 | 23.9±6.5 |
| **Fasting glucose (mmol/l)** | 5.11±0.57  | 5.68±0.50 |
| **Glucose, 120 min OGTT (mmol/l)** | 6.26±1.67  | 6.09±1.69 |
| **Fasting insulin (pmol/l)** | 65.2±51.1 | 48.6±33.7 |
| **Insulin, 30 min OGTT (pmol/l)** | 424±443  | 391±284 |

Data are given as means ±SD. BMI – body mass index; IFG – impaired fasting glucose (defined as 100–126 mg/dl according to AHA guidelines); IGT – impaired glucose tolerance; OGTT – oral glucose tolerance test.

doi:10.1371/journal.pone.0013980.t001
Analytical procedures

A bedside glucose analyzer (Yellow Springs Instruments, Yellow Springs, OH, USA) was used to measure blood glucose. Plasma insulin was measured by chemical luminescence assays from ADVIA Centaur (Siemens Medical Solutions, Fernwald, Germany; unit: pmol/l). In the METSIM Study, plasma insulin was measured by immunnooay (ADVIA Centaur Insulin IRI, no 02230141, Siemens Medical Solutions Diagnostics, Tarrytown, NY; unit: mU/l) according to the manufacturer’s instructions.

Oral glucose tolerance test (OGTT)

TUF/TULIP and METSIM participants were investigated in the fasting state at baseline. Subsequently, all participants underwent an OGTT performed according to the WHO recommendations [37]. Blood glucose and plasma insulin were determined at 0, 30, 60, 90 and 120 min in the TUF/TULIP Study and at 0, 30, and 120 min in the METSIM Study.

Determination of body and liver fat

The body mass index (BMI) was calculated as weight divided by the square of height (kg/m²). Body fat was determined by bioelectrical impedance (RJL; Detroit, MI, USA). In the TULIP cohort, liver fat was determined by magnetic resonance spectroscopy (1.5 T Magnetom Sonata; Siemens, Erlangen, Germany) in the posterior 7th segment of the liver. A single-voxel stimulated echo acquisition mode technique was used (repetition time = 4 s, echo time = 10 msec, 32 acquisitions) for a voxel of 3x3x2 cm³, and liver fat content was calculated by the signal integral (methylen/methyl signals between 0.7–1.5 ppm) in reference to the sum of water and lipid signal integrals [38,39].

Insulin sensitivity

Insulin sensitivity was estimated using the Matsuda model [40] in both study cohorts, based on plasma glucose and plasma insulin levels obtained at 0, 30, 60, 90 and 120 min in TUF/TULIP and 0, 30, 120 min in METSIM, respectively. In the METSIM cohort, we additionally used the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) for estimation of insulin resistance [41]. In N = 502 TUF/TULIP participants, an additional hyperinsulinemic euglycaemic clamp was undertaken during a second visit. Further details on the clamping technique are described elsewhere [42].

Genotyping

The SNP rs4986790 (exon 3) encoding the D299G mutation in the extracellular domain of TLR4 was genotyped by use of the TaqMan assay (Eurogentec; Liège, Belgium) and the fluorescence detecting ABI Prism 7500 (Applied Biosystems; Foster City, CA, USA). To verify the reported co-segregation of rs4986790 (exon 3, D299G) with rs4986791 (exon3, T399I; D’ = 1.0, r² = 1.0) in the CEU population, HapMap Ref #24 PhaseII Nov06 [20] and TaqMan validity in our cohort, we sequenced for both SNPs in N = 388 German participants, verifying the reported linkage disequilibrium (D’ = 1.0, r² = 1.0). Genotyping quality was ensured by including three sequenced controls of each rs4986790 genotype in the TaqMan assay plates.

Statistics

The JMP 4.0.4 software (SAS Institute; Cary, NC, USA) and SPSS 14.0 for Windows (SPSS Inc., Chicago, IL, USA) were used for statistical analysis. Data are presented as means ± SD if not otherwise stated. The χ²-test was used for testing Hardy-Weinberg-Equilibrium. All non-normally distributed parameters were logarithmically transformed before analysis by ANOVA or t-tests without adjustment or with adjustment to relevant covariates in linear regression models. A p value≤0.05 was considered statistically significant.

Results

Distribution of D299I-TLR4 genotypes

The genotype call rate for rs4986790 was 98.2/100% in the TUF/TULIP and the METSIM Study, respectively. The minor allele frequency of rs4986790 was 0.052 in TUF/TULIP and 0.094 in METSIM, and both genotype distributions were in Hardy-Weinberg-Equilibrium (TUF/TULIP: p = 0.56; METSIM: p = 0.64).

D299G-TLR4 association analyses in TUF/TULIP

Associations in this population were only calculated based on a dominant model owing to the low minor allele frequency of rs4986790 in TUF/TULIP, resulting in 3 homozygote minor allele carriers. The minor allele carriers of rs4986790 had a significantly increased body fat (e.g. XG: +6.98%, p = 0.03 in the dominant model adjusted for age and gender, see Table 2), and an allele-dose effect on body fat could be assumed (AG: +6.9%, GG: +9.2%; see also results of METSIM below). There was no significant association between rs4986790 genotype and BMI or blood glucose (both 0 and 120 min OGTT) levels (p>0.06; all). In contrast, insulin sensitivity was significantly decreased in rs4986790 minor allele carriers, independently of whether the Matsuda estimation model (XG: −15.3%) or insulin sensitivity data measured by clamp (XG: −20.6%) were used for analysis. This association remained significant after adjustment for age, gender and BMI (see Table 2) or body fat (Matsuda: p = 0.04; clamp: p = 0.016; dominant model). We additionally stratified the TUF/TULIP cohort for gender, as the METSIM cohort only includes male participants. While the association with body fat (p = 0.04, adjusted for age; dominant model) and insulin sensitivity (Matsuda: p = 0.002; clamp: p = 0.013, both adjusted for age, gender and BMI; dominant model) was more significant in males, both association analyses turned out to be non-significant in women (body fat: p = 0.24, Matsuda/clamp: p>0.05).

As liver fat is an important determinant for insulin resistance [43], we subsequently analyzed whether the rs4986790 genotype also associates with liver fat measured by magnetic resonance imaging (MRI). Indeed, liver fat was significantly increased in heterozygous rs4986790 minor allele carriers (AG: +49.7%; N = 297, no liver fat data from homozygous carriers available; see Figure 1). In addition, visceral adipose tissue (VAT) content in rs4986790 SNP carriers was significantly higher (Matsuda: p = 0.002; clamp: p = 0.013, both adjusted for age, gender and BMI; dominant model) more significant in males, both association analyses turned out to be non-significant in women (body fat: p = 0.24, Matsuda/clamp: p>0.05).

D299I-TLR4 association analyses in METSIM

The association of rs4986790 genotype with body fat was reproducible in METSIM (AG: +1.26%, GG: +1.0%; p = 0.010, additive model, see Table 3). Similarly as in TUF/TULIP, BMI and blood glucose levels were not associated with the rs4986790 genotype (p>0.10; all). Insulin sensitivity (Matsuda model) also decreased in rs4986790 G allele carriers (AG: −0.99%, GG: −0.53%.)
cholesterol (TC/HDL-C) was not significant (rs4986790 genotype by the ratio of total-cholesterol:HDL-
olink{} to the findings of Kolz et al. [30], interaction analysis of TLR4
was, therefore, not admissible.

Stratification of the METSIM cohort for TC/HDL-C

doi:10.1371/journal.pone.0013980.g001

Liver fat was determined by magnetic resonance imaging

Figure 1. Liver fat according to D299G-TLR4 (rs4986790)

doi:10.1371/journal.pone.0013980.t002

* N = 502.

Table 2. Associations of TLR4 SNP rs4986790 (D299G) with anthropometric and metabolic data in the TUF-TULIP cohort (N = 1482).

| SNP          | rs4986790 | Genotype | AA | AG | GG | dominant model |
|--------------|-----------|----------|----|----|----|----------------|
|              |           |          |    |    |    | P<sub>1</sub> | P<sub>2</sub> |
| N            |           |          | 1330 | 149 | 3 |     |     |
| Age (y)      |           |          | 39±13 | 39±13 | 29±3 | 0.86 | 0.96 |
| BMI (kg/m²)  |           |          | 28.4±7.8 | 29.5±8.6 | 29.9±10.2 | 0.11 | 0.13 |
| Body Fat (%) |           |          | 30.2±10.4 | 32.3±10.7 | 33.0±18.0 | **0.02** | 0.03 |
| Fasting glucose (mM) | |          | 5.11±0.57 | 5.17±0.58 | 4.84±0.15 | 0.25 | 0.42 |
| Glucose, 120 min OGTT (mM) | |          | 6.23±1.67 | 6.48±1.59 | 7.30±1.92 | 0.06 | 0.09 |
| Insulin sensitivity (Matsuda), OGTT (AU) | |          | 16.8±11.0 | 14.26±9.0 | 11.33±6.1 | **0.004** | 0.03 |
| Insulin sensitivity, clamp (U)* | |          | 0.087±0.056 | 0.069±0.046 | 0.069±0.069 | **0.026** | 0.04 |

Data are given as means ± SD. P<sub>1</sub> – non-adjusted model; P<sub>2</sub> – adjusted model with log-transformed data; age was adjusted for gender; BMI and body fat were adjusted for gender and age; glucose levels as well as insulin sensitivity (Matsuda estimation model, clamp) were adjusted for gender, age, and BMI; BMI – body mass index; OGTT – oral glucose tolerance test; SNP – single nucleotide polymorphism.

Discussion

This is the first study to have investigated the role of the TLR4<sup>ΔD299G/T399I</sup> double mutant for body fat composition and insulin resistance in non-diabetic populations at increased diabetes risk. Our finding is a consistent association of the minor allele of the selected tagging SNP rs4986790 with increased body fat in both the TUF/TULIP and the METSIM study cohort. The effect on body fat was remarkable in both populations, especially in homozygous minor allele rs4986790 carriers (+9.2% and +11.0%, respectively). In the German cohort, there were also significant associations of the minor G allele in rs4986790 with increased insulin resistance, increased liver fat and increased visceral fat in adjusted linear models. In METSIM, there was only a non-significant trend to reduced insulin sensitivity. We assume that this finding may be a consequence of the different structure of both study populations. In METSIM, participants were selected randomly from the population of Kuopio and are older by an average of 20 years, while TUF/TULIP comprises mainly non-diabetic individuals at a younger age, selected based on the assumption of an increased diabetes risk.

The link between the innate immune system and obesity comes from common features of both macrophages and adipocytes. Both cell types secrete various pro-inflammatory chemokines and cytokines and intensely interact yet due to their close physical location in adipose tissue [44,45], and both adipocytes and macrophages express TLR4 on their plasma membrane [4,10]. TLR4 expression in visceral adipose tissue (VAT) of obese subjects exceeds that of the subcutaneous fat compartment, in contrast to lean individuals, where TLR4 is expressed more in subcutaneous fat compared to VAT [46]. A recent study also showed that TLR4 expression is increased on VAT-derived macrophages from both obese and diabetic individuals, and that both adipocyte size and systemic CRP levels are increased according to macrophage infiltration and TLR4 expression [47]. Taken together, these data yet support our finding that a TLR4 variant impacts on body fat composition and insulin resistance.

Above mentioned studies let assume that the TLR4<sup>ΔD299G/T399I</sup> double mutant confers an intrinsic activation to TLR4, at least in adipose tissue and liver fat. However, functional assays with TLR4<sup>ΔD299G/T399I</sup> revealed inconclusive results. While some authors reported hypo-responsiveness of this TLR4 mutant to stimuli like e.g. LPS [25], other groups could not verify any
differences in receptor functionality comparing TLR4D299G/T399I to wildtype TLR4 [27]. Therefore, future studies should address adipocyte TLR4 signaling in adipose tissue samples derived from TLR4D299G/T399I carriers to finally address this issue.

One could speculate that differences in serum free fatty acid (FFA) levels may have contributed to the reported phenotype with higher body fat content. However, serum FFA levels did not differ in TUF/TULIP according to TLR4 genotype, and systemic cytokines (TNFα, IL6) as a possible readout of inflammatory activity were also not altered significantly (data not shown). As the effect on liver fat was independent of the increased VAT content in German TLR4D299G/T399I carriers, we assume that the observed increase in ectopic hepatic fat may be a consequence from altered direct crosstalk between hepatic macrophages and adipocytes, and not an epiphenomenon caused by potential VAT mediator release. It is well known that liver fat generally associates with insulin resistance [40,49], but we also have learned that this association is subject to remarkably high variability [43]. Taking into account that the increase in liver fat in TLR4D299G/T399I carriers comes along with decreased insulin sensitivity in TUF/TULIP, one may speculate whether TLR4 may represent a candidate for the mediation of metabolically unfavorable effects of liver fat.

The limitation of our study is that Bonferroni’s correction for 3 independent endpoints (body fat, plasma glucose, insulin sensitivity) expected α-level: 0.017 would render the reported finding for body fat composition nominal. In addition, the increase in body fat in non-diabetic individuals was not reflected by a significant increase in diabetes prevalence in the METSIM study.

In summary, we conclude that the TLR4D299G/T399I double mutant is associated with increased body fat and insulin resistance. Due to its low allele frequency throughout different populations [21], TLR4D299G/T399I cannot be seen as a strong obesity or diabetes risk gene, but may contribute to factors that are well known to entail a relevant predisposition to later onset of type 2 diabetes mellitus.

**Acknowledgments**

We gratefully acknowledge the technical assistance of Melanie Weisser, Alke Guirguis, Roman Werner and Anna Bury. The authors would also like to thank all participants for their cooperation.

**Author Contributions**

Conceived and designed the experiments: PW NS ML AF HUH. Performed the experiments: FM JM FS ML HUH. Analyzed the data: PW HS AS JK AF. Contributed reagents/materials/analysis tools: FM JM FS ML HUH. Wrote the paper: PW. Revised/edited the manuscript: HS AS FS NS JK ML SAS AF HUH. Contributed to discussion: HS AS FM JM FS NS JK ML SAS AF HUH.

**References**

1. Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, et al. (2006) Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine News 17: 4–12.
2. Zimmet P, Alberti KG, Shaw J (2001) Global and societal implications of the diabetes epidemic. Nature 414: 782–787.
3. Fessler MB, Rudel LL, Brown JM (2009) Toll-like receptor signaling links dietary fatty acids to the metabolic syndrome. Curr Opin Lipidol. 4. Medzhitov R (2001) Toll-like receptors and innate immunity. Nat Rev Immunol 1: 135–145.
5. Gay NJ, Gangloff M (2007) Structure and function of Toll receptors and their ligands. Annu Rev Biochem 76: 141–165.
6. O’Neill LA (2008) The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress. Immunol Rev 299: 10–18.
7. Krishnan J, Selvarajoo K, Tschaichi M, Lee G, Choi S (2007) Toll-like receptor signal transduction. Exp Mol Med 39: 421–438.
8. Kaelin CR, Whitefield G (2002) Lipopolysaccharide endotoxins. Annu Rev Biochem 71: 635–700.
9. Lee YJ, Sohn KH, Rhie SH, Hwang D (2001) Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4. J Biol Chem 276: 16683–16689.
10. Song MJ, Kim KH, Yoon JM, Kim JB (2006) Activation of Toll-like receptor 4 is associated with insulin resistance in adipocytes. Biochem Biophys Res Commun 346: 739–745.
11. Shi H, Kokoeeva MV, Inouye K, Tzameli I, Yin H, et al. (2006) TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 116: 3015–3025.
12. Radin MS, Sinha S, Bhutt BA, Dedousis N, O'Doherty RM (2008) Inhibition or deletion of the lipopolysaccharide receptor Toll-like receptor-4 confers partial protection against lipid-induced insulin resistance in rodent skeletal muscle. Diabetologia 51: 336–346.
13. Suganuma T, Tanimoto-Koyama K, Nishida J, Itoh M, Yuan X, et al. (2007) Role of the Toll-like receptor 4/NF-kappaB pathway in saturated fatty acid-induced inflammatory changes in the interaction between adipocytes and macrophages. Atheroscler Thromb Vasc Biol 27: 84–91.
14. Tsaknino DM, Carvalho-Filho MA, Carvalheiro JB, Prado PO, Hirabara SM, et al. (2007) Loss-of-function mutation in Toll-like receptor 4 prevents diet-induced obesity and insulin resistance. Diabetes 56: 1986–1998.
15. Poggi M, Bastestta D, Gaul P, Iglesias MA, Gremaux T, et al. (2007) CI91/HcJ mice carrying a toll-like receptor 4 mutation are protected against the development of insulin resistance in white adipose tissue in response to a high-fat diet. Diabetologia 50: 1267–1276.

**Table 3. Associations of TLR4 SNP rs4986790 (D299G) with anthropometric and metabolic data in the METSIM cohort (N = 5327).**

| Genotype | rs4986790 | additive | dominant |
|----------|-----------|----------|----------|
| Genotype | AA | AG | GG | P1 | P2 | P1 | P2 |
| N | 4375 | 902 | 50 | | | | |
| Age (y) | 58±6 | 59.7 | 59.7 | 0.57 | 0.29 | - | |
| BMI (kg/m²) | 26.9±3.8 | 26.7±3.8 | 27.8±3.7 | 0.10 | 0.10 | 0.58 | 0.59 |
| Body Fat (%) | 23.9±6.6 | 24.2±6.6 | 26.5±6.7 | 0.015 | 0.010 | 0.10 | 0.19 |
| Fasting glucose (mM) | 5.68±0.50 | 5.69±0.49 | 5.71±0.53 | 0.77 | 0.67 | 0.48 | 0.41 |
| Glucose, 120 min OGTT (mM) | 6.08±1.68 | 6.13±1.74 | 6.33±1.65 | 0.43 | 0.61 | 0.39 | 0.38 |
| Insulin sensitivity (Matsuda), OGTT (AU) | 7.05±4.19 | 6.97±4.14 | 6.31±3.27 | 0.61 | 0.36 | 0.46 | 0.21 |
| Insulin resistance index (HOMA-IR), OGTT (AU) | 2.078±1.509 | 2.080±1.535 | 2.121±1.335 | 0.83 | 0.52 | 0.76 | 0.38 |

Data are given as means ±SD. p values were calculating using log-transformed variables. p1 = non-adjusted model; p2 = adjusted model as follows: BMI and body fat were adjusted for age; glucose levels as well as insulin sensitivity (Matsuda estimation model; Homeostasis Model Assessment of Insulin Resistance: HOMA-IR) were adjusted for age and BMI; BMI – body mass index; OGTT – oral glucose tolerance test; SNP – single nucleotide polymorphism.

doi:10.1371/journal.pone.0013980.t003
16. Wong SW, Kwon MJ, Choi AM, Kim HP, Nakahira K, et al. (2009) Fatty acids modulate toll-like receptor 4 activation through regulation of receptor dimerization and recruitment into lipid rafts in a dos-dependent manner. J Biol Chem.

17. Krivoy SM, Ghosh S, Tantwongw P, Meka GS, Eagan P, et al. (2008) Elevated toll-like receptor 4 expression and signaling in muscle from insulin-resistant subjects. Diabetes 57: 2595–2602.

18. de Mello VD, Kolehmainen M, Pulkkinen L, Schwab U, Mager U, et al. (2008) Downregulation of cytokines involved in NFκB activation in peripheral blood mononuclear cells after weight loss is associated with the improvement of insulin sensitivity in individuals with the metabolic syndrome: the GENOBIN study. Diabetologia 51: 2060–2067.

19. Skàrovà ST, Ward MH, Khedows M, Baker J, Phan L, et al. (2001) dbSNP: the NCBI database of genetic variation. Nucleic Acids Res 29: 308–311.

20. (2003) The International HapMap Project. Nature 426: 789–796.

21. Ferwerda B, McCall MB, Alonso S, Giamarellos-Bourboulis EJ, Mouktaroudi M, et al. (2007) TLR4 polymorphisms, infectious diseases, and evolutionary pressure during migration of modern humans. Proc Natl Acad Sci U S A 104: 16654–16659.

22. Ferwerda B, McCall MB, Verheijen K, Kullberg BJ, van der Ven AJ, et al. (2008) Functional consequences of toll-like receptor 4 polymorphisms. Mol Med 14: 346–352.

23. Awomoyi AA, Rallabhandi P, Pollini TI, Lorenz E, Szein MB, et al. (2007) Association of TLR4 polymorphisms with symptomatic respiratory syncytial virus infection in high-risk infants and young children. J Immunol 179: 3171–3177.

24. Bochud PY, Chien JW, Marr KA, Leisenring WM, Upton A, et al. (2008) Toll-like receptor 4 polymorphisms and infectious diseases, and evolutionary pressure during migration of modern humans. Proc Natl Acad Sci U S A 104: 1708–1713.

25. Arbour NC, Lorenz E, Schutte BC, Zahnert J, Kline JN, et al. (2008) TLR4 mutations are associated with endotoxin hyperresponsiveness in humans. Nat Genet 25: 187–191.

26. Sinimova I, Mann N, Dols A, Derks HH, Hibberd ML, et al. (2005) Assay of loci-specific genetic load implicates rare Toll-like receptor 4 mutations in meningococcal susceptibility. Proc Natl Acad Sci U S A 100: 6075–6080.

27. van der Graaf G, Kullberg BJ, Joosten L, Verkerk-Jansen T, Jacobs L, et al. (2005) Functional consequences of the Asp299Gly Toll-like receptor-4 polymorphism. Immunology 109: 264–268.

28. Petekova C, Emmanuelidis K, Mietheke T, Gerauer K, Rump M, et al. (2003) Effects of functional Toll-like receptor-4 mutations on the immune response to human and experimental sepsis. Immunology 109: 426–431.

29. Ilig T, Bongardt F, Schopfer A, Holle R, Muller S, et al. (2003) The endotoxin receptor TLR4 polymorphism is not associated with diabetes or components of the metabolic syndrome. Diabetes 52: 2861–2864.

30. Kolz M, Baumert J, Muller M, Khuseyinova N, Koppel N, et al. (2008) Association between variations in the TLR4 gene and incident type 2 diabetes is modified by the ratio of total cholesterol to HDL-cholesterol. BMC Med Genet 9: 9.

31. Buraczynska M, Baranowicz-Gaszycky I, Tarach J, Ksiązeck A (2009) Toll-like receptor 4 gene polymorphism and early onset of diabetic retinopathy in patients with type 2 diabetes. Hum Immunol 70: 121–124.

32. Rudolky G, Jr., Reimann P, Witte S, Humpert PM, Iermann B, et al. (2004) Asp299Gly and Thr399Ile genotypes of the TLR4 gene are associated with a reduced prevalence of diabetic neuropathy in patients with type 2 diabetes. Diabetes Care 27: 179–183.

33. Bagaroli RA, Saad MJ, Saad ST (2009) Toll-like receptor 4 and inducible nitric oxide synthase gene polymorphisms are associated with Type 2 diabetes. J Diabetes Complications.

34. Steinhardt AP, Arangure F, Tellechea ML, Gomez Rosso LA, Brites FD, et al. (2010) A functional nonsynonymous toll-like receptor 4 gene polymorphism is associated with metabolic syndrome, surrogates of insulin resistance, and syndromes of lipid accumulation. Metabolism 59: 711–717.

35. Schafer S, Kantartzis K, Machann J, Venter C, Niesa A, et al. (2007) Lifestyle intervention in individuals with normal versus impaired glucose tolerance. European Journal of Clinical Investigation 37: 553–563.

36. Alberti KG, Zimmet PZ (1998) Definition, diagnosis, and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15: 539–553.

37. Alberti KG, Zimmet P, Shaw J (2005) The metabolic syndrome–a new worldwide definition. Lancet 366: 1059–1062.

38. Machann J, Thamer C, Schnoedt B, Haap M, Haring HU, et al. (2005) Standardized assessment of whole body adipose tissue topography by MRI. J Magn Reson Imaging 21: 455–462.

39. Stefan N, Machicao F, Staiger H, Machann J, Schick F, et al. (2005) Polymorphisms in the gene encoding adiponectin receptor 1 are associated with insulin resistance and high liver fat. Diabetologia 48: 2292–2299.

40. Matsuda M, DeFranco RA (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22: 1462–1470.

41. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412–429.

42. Weyrich P, Machicao F, Staiger H, Simson P, Thamer C, et al. (2007) Role of AMP-activated protein kinase gamma 3 genetic variability in glucose and lipid metabolism in non-diabetic whites. Diabetologia 50: 2097–2106.

43. Stefan N, Kantartzis K, Haring HU (2008) Causes and metabolic consequences of fatty liver. Endocr Rev 29: 939–960.

44. MacLaren R, Cai W, Gianfalone K (2008) Adipokines and the immune system: an adipocentric view. Adv Exp Med Biol 632: 1–21.

45. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G (2001) Adipose tissue TNF-α expression and tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 280: E745–751.

46. Weyrich P, Machanno F, Staiger H, Machann J, Schick F, et al. (2005) TLR4 polymorphisms, infectious diseases, and evolutionary pressure during migration of modern humans. Proc Natl Acad Sci U S A 100: 6075–6080.

47. van der Graaf G, Kullberg BJ, Joosten L, Verkerk-Jansen T, Jacobs L, et al. (2005) Functional consequences of the Asp299Gly Toll-like receptor-4 polymorphism. Immunology 109: 264–268.

48. Feterowski C, Emmanuilidis K, Miethke T, Gerauer K, Rump M, et al. (2003) Functional consequences of toll-like receptor 4 polymorphisms. Mol Med 14: 346–352.

49. Thamer C, Machann J, Stefan N, Haap M, Schafer S, et al. (2007) Role of TLR4 polymorphisms, infectious diseases, and evolutionary pressure during migration of modern humans. Proc Natl Acad Sci U S A 104: 16654–16659.